相关实验视频

Updated: May 2, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

在一个耐火性多发性骨髓瘤患者中,Teclistamab揭示了渐进性多焦点白血脑病

Panos Arvanitis¹, Dimitrios Farmakiotis¹, Ari Pelcovits²

¹Division of Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Gerry House 111, Providence, RI 02903, USA.

Current oncology (Toronto, Ont.)

|May 24, 2024

概括

一名72岁的多发性骨髓瘤患者在COVID-19感染期间服用了一剂teclistamab后出现了渐进性多焦点白细胞大脑病变 (PML). 这突显了这种有前途的RRMM治疗严重感染的风险.

科学领域:

神经免疫学神经免疫学
在瘤学瘤学.
传染性疾病传染性疾病

背景情况:

复发性/耐药性多发性骨髓瘤 (RRMM) 存在重大治疗挑战.
德基利斯塔马布为RRMM提供了一个有前途的治疗选择.
免疫受损状态增加了对机会性感染的易感性.

研究的目的:

报告一个罕见的进展性多焦点白细胞脑病变 (PML) 病例,该病例发生在RRMM患者中,该患者接受了teclistamab治疗.
为了突出与德克利斯塔马布治疗相关的潜在传染性并发症.

主要方法:

一个72岁的男性患有RRMM的病例报告.
临床表现和神经症状的诊断工作.
在脑脊液中通过PCR检测JC病毒,以诊断PML.

主要成果:

这位患者在同时感染COVID-19期间服用单剂Teclistamab后发展出PML.
症状包括发烧,精神状态变化和右侧半.
JC病毒PCR证实了PML的诊断.

结论:

德基利斯塔马布虽然对RRMM有希望,但存在严重机会性感染的风险,如PML.
在接受新型免疫治疗的患者中,早期识别和诊断PML至关重要.
一次剂量后发生的PML需要进一步调查风险因素和监测策略.

关键词:

渐进性多焦点白细胞大脑病变两种特异性的抗体.多发性骨髓瘤是多发性骨髓瘤的一种.德克里斯塔马巴巴是什么意思

更多相关视频

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...